P. Hunter Philbrick serves as Independent Director of the Company. Mr. Philbrick has served as a Partner at Hellman & Friedman since January 2013. Prior to joining Hellman & Friedman in 2003, Mr. Philbrick worked as an investment banker in the mergers, acquisitions and restructuring and general industrial departments of Morgan Stanley & Co (MS). He currently serves as a member of the board of directors of HUB International Limited, a global insurance brokerage, and MultiPlan, Inc., a healthcare cost management service provider. Mr. Philbrick was formerly a director of Change Healthcare Inc. (CHNG) (formerly Emdeon), an independent healthcare technology platform, GeoVera Insurance Holdings Ltd., a residential property insurance company, and Sedgwick Inc., a provider of technology-enabled risk, benefits and integrated business solutions.
P Philbrick is 40, he's been the Independent Director of PPD Inc since . There are 16 older and 2 younger executives at PPD Inc. The oldest executive at PPD Inc is Jeffrey Kindler, 64, who is the Independent Director.
P's mailing address filed with the SEC is C/O PPD, INC.,, 929 NORTH FRONT STREET, WILMINGTON, NC, 28401.
Over the last 22 years, insiders at PPD Inc have traded over $14,532,346,241 worth of PPD Inc stock and bought 130,455 units worth $3,520,800 . The most active insiders traders include Corporate Investors Viii, L..., Corporate Investors Vii, Lt..., and Group Management L.L.C.Carl.... On average, PPD Inc executives and independent directors trade stock every 53 days with the average trade being worth of $124,899,671. The most recent stock trade was executed by Corporate Investors Viii, L... on 8 December 2021, trading 132,841,266 units of PPD stock currently worth $6,309,960,135.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Company's customers include pharmaceutical, biotechnology, medical device, academic and government organization s. With offices in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.
PPD Inc executives and other stock owners filed with the SEC include: